Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

NCT03966118 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Junction Adenocarcinoma
Adenocarcinoma of the Stomach

Interventions

DRUG: Avelumab
DRUG: Ramucirumab
DRUG: Paclitaxel

Sponsor

P. C. Thuss-Patience